Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome
Authors:
Open Access
- 1 November 2021
- Vol. 78 (21) , 2076-2088
Abstract
No abstract availableKeywords
Funding Information
- Biotronik
- National Institutes of Health (HL-123483, HL-33843, HL-51618)
- LivaNova
This publication has 23 references indexed in Scilit:
- Reduction in Inappropriate Therapy and Mortality through ICD ProgrammingNew England Journal of Medicine, 2012
- Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?Circulation, 2010
- Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During InfancyJACC, 2009
- Long QT SyndromeCurrent Problems in Cardiology, 2008
- Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT SyndromeCirculation, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Long QT Syndrome in AdultsJACC, 2007
- Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: A long-term follow-upHeart Rhythm, 2005
- Implantable Cardioverter Defibrillator in High‐Risk Long QT Syndrome PatientsJournal of Cardiovascular Electrophysiology, 2003
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002